Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2019-04-15 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
关于对公司控股股东及其他关联方占用资金情况的专项说明
Audit Report / Information Classification · 95% confidence The document is a detailed special explanation regarding the use of funds by the controlling shareholder and other related parties of Jiangsu Sihuan Bio Co., Ltd. It includes references to audited financial statements for the year ended December 31, 2018, and mentions an audit report issued on April 14, 2019. The document is issued by a certified public accounting firm and contains tables summarizing non-operating fund occupation and related party transactions. It is a standalone audit-related document focusing on compliance with regulatory requirements about related party fund usage, not a full annual report or interim report. It is not a mere announcement or certification but contains substantive audit findings and explanations. Therefore, it fits the category of an Audit Report / Information (AR). The document length (15,000 characters) and content confirm it is a full report, not just an announcement or certification.
2019-04-15 Chinese
2018年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2018 年年度报告摘要" which translates to "2018 Annual Report Summary". It contains detailed financial data for the year 2018, including revenue, net profit, earnings per share, and other financial indicators. It also discusses business operations, industry context, shareholder information, and accounting policy changes. The document is about 8906 characters long, which is substantial and contains actual financial data and analysis, not just an announcement or a brief summary. It is clearly a financial report covering the full fiscal year 2018. Therefore, this document fits the definition of an Annual Report (10-K). FY 2018
2019-04-15 Chinese
2018年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report for the Year 2018" from Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. It details the independent directors' attendance at board meetings, their independent opinions on various board resolutions, their role in protecting investor rights, and their participation in the audit of the 2017 annual report. The document is a narrative report on the independent directors' duties and activities over the year, rather than a financial report or an announcement. It does not contain financial statements or earnings data, nor is it a regulatory filing or announcement of voting results. It is a management-related report focusing on board activities and oversight, fitting best under Board/Management Information (MANG). The document length is about 3206 characters, which is relatively short but contains substantive content about board activities and independent director duties, not just an announcement or certification. Therefore, the classification is MANG with high confidence.
2019-04-15 Chinese
关于2018年度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's 2018 asset impairment provision. It includes details on the amount of impairment, accounting basis, board and independent director opinions, and supervisory board review. The document is relatively short (1518 characters) and serves as a formal disclosure of a specific accounting action rather than a full financial report. It does not contain comprehensive financial statements or detailed management discussion. It is not an annual or interim report, nor an earnings release. It is a regulatory announcement about asset impairment provisioning, which fits best under Regulatory Filings (RNS) as it does not meet criteria for other specific report types.
2019-04-15 Chinese
第八届监事会第九次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board meeting of Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. It details the approval of various reports and proposals related to the 2018 fiscal year, including the annual report, supervisory board work report, financial statements, profit distribution plan, internal control evaluation report, asset impairment provision, accounting policy changes, and opinions on audit reports. The document is relatively short (1523 characters) and serves as a formal announcement of the meeting's resolutions rather than the full reports themselves. It does not contain the full annual report or detailed financial statements but rather the decisions to submit these reports to the shareholders' meeting. Therefore, it is best classified as a Regulatory Filing (RNS) because it is an official announcement of board resolutions and approvals related to annual reports and financial matters, not the reports themselves.
2019-04-15 Chinese
2018年度财务决算报告
Annual Report Classification · 95% confidence The document is titled as a 2018 annual financial settlement report for Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. It contains detailed financial data including revenue, net profit, asset composition, cash flow, expenses, and cost breakdowns for the year 2018 compared to previous years. The report mentions an audit by an accounting firm with an unqualified opinion and includes comprehensive financial statements and analysis. The length of the document (6017 characters) and the detailed financial content indicate it is a full financial report rather than a brief announcement or certification. The document is clearly an annual financial report covering the full fiscal year 2018, consistent with the definition of an Annual Report (10-K). FY 2018
2019-04-15 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.